401
Participants
Start Date
March 31, 2002
Primary Completion Date
March 31, 2011
Study Completion Date
March 31, 2011
Capecitabine
Capecitabine standard therapy (i.e. 2,500 mg/sqm) x 5 cycles plus 1 cycle of capecitabine based chemoradiotherapy (1.650 mg/sqm)
5-FU
4 cycles of bolus 5-FU (500 mg/sqm) and 1 cycle of 5-FU based chemoradiotherapy (either 1,000 mg/sqm/day infusional 5-Fu days 1-5 and 29-33 or 225 mg/sqm/day infusional 5-Fu throughout the time of chemoradiotherapy)
Dr Martina Grunewald, Aschersleben
Dr Hans Walter Lindemann, Hagen
Prof Hartmut Link, Kaiserslautern
Dr Elisabeth Fritz, Koblenz
Dr Stephan Kremers, Lebach
Dr Lothar Müller, Leer
Dr Christain Constantin, Lemgo
Dr Erika Kettner, Magdeburg
Dr Markus Moehler, Mainz
Dr Udo Hieber, Mannheim
Prof Ralf Hofheinz, Mannheim
Dr Matthias Hipp, Regensburg
Prof Axel Matzdorff, Saarbrücken
Dr Stephan Laechelt, Tübingen
Universitätsmedizin Mannheim
OTHER